



VIA REGISTERED POST AND EMAIL

**Attention: Ms Zhang Liqin**

*GM-Sales & Marketing*

*Aurisco Pharmaceutical Co., Ltd*

*Room 1701, 488 South Wuning Road, Shanghai 200042 .R.R China*

*Email: zhangliqin@aurisco.com*

*Date: 29 August 2025*

**Re: Notice of Termination for the Nirmatrelvir Licence Agreement**

Dear Ms Zhang Liqin,

We refer to the licence agreement between the Medicines Patent Pool ("**MPP**") and Aurisco Pharmaceutical Co., Ltd ("**Licensee**") dated 17/05/2022 concerning patents and know-how pertaining to nirmatrelvir ("**Licence Agreement**").

MPP is entitled to terminate this Licence Agreement with immediate effect pursuant to Section 12.3(c) of the Licence Agreement, as the Licensee failed to fulfill its obligation under Section 3.7, specifically the requirement to submit a complete file for WHO Prequalification or any SRA approval within thirty-six (36) months from the Effective Date for any existing formulation of the Products.

As such, please accept this letter as formal notice that, without any further written notice, MPP hereby terminates the Licence Agreement with effect from 29 August 2025.

This Licence Agreement is hereby terminated without prejudice to the surviving provisions of the Licence Agreement under section 12.10.

Sincerely,

For and on behalf of Medicines  
Patent Pool

A handwritten signature in black ink, appearing to be "Chan Park", written over a horizontal line.

Name: Chan Park

Title: General Counsel

Date: 29 August 2025